<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814032</url>
  </required_header>
  <id_info>
    <org_study_id>AHInnerMongolia-Thyroid-02</org_study_id>
    <nct_id>NCT02814032</nct_id>
  </id_info>
  <brief_title>Proteomics of Papillary Thyroid Carcinoma</brief_title>
  <official_title>Differences Protein Expression in Papillary Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Inner Mongolia Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Inner Mongolia Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thyroid carcinoma is the common endocrine system malignant neoplasm. At present it has become
      the malignant neoplasm of fastest growing incidence rate. More than 85% thyroid carcinoma is
      papillary thyroid carcinoma. Cervical lymph node metastasis is common in papillary thyroid
      carcinoma patients. This study aim to reveal protein expression differences between papillary
      thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node
      metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Object: Patients aged 18-65 years; newly diagnosed papillary thyroid carcinoma with
           cervical lymph node metastasis and without cervical lymph node metastasis and undergone
           thyroidectomy according to the China thyroid association guidelines for the Management
           of thyroid nodule and thyroid cancer.

        2. Clinical information, examination data: Information is obtained from medical record
           abstraction.

        3. Samples: Fresh frozen thyroid tissues from each sample group(normal histology, benign
           disease, papillary thyroid carcinoma with cervical lymph node metastasis, papillary
           thyroid carcinoma without cervical lymph node metastasis ).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>differences in protein expression</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Papillary Thyroid Carcinoma</condition>
  <arm_group>
    <arm_group_label>PTC group 1</arm_group_label>
    <description>papillary thyroid carcinoma patients with cervical lymph node metastasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTC group 2</arm_group_label>
    <description>papillary thyroid carcinoma patients without cervical lymph node metastasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive control group</arm_group_label>
    <description>benign disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative control group</arm_group_label>
    <description>histologically normal</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 18-65 years; newly diagnosed papillary thyroid carcinoma with cervical lymph
        node metastasis and without cervical lymph node metastasis and undergone thyroidectomy
        according to the China thyroid association guidelines for the Management of thyroid nodule
        and thyroid cancer.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed papillary thyroid carcinoma.

          -  Undergo thyroidectomy according to the China thyroid association guidelines forthe
             Management of thyroid nodule and thyroid cancer.

        Exclusion Criteria:

          -  Current substance abuse/dependence.

          -  Daily tobacco and alcohol use.

          -  Whole neck irradiation or surgery.

          -  Prior cancer diagnosis or chemotherapy treatment.

          -  Active autoimmune disorder.

          -  Uncontrolled allergic condition or asthma.

          -  Chronic use of oral steroid medication.

          -  Hormone therapy (estrogen, progestin compounds).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shan Jin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Hospital of Inner Mongolia Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shan Jin, PhD</last_name>
    <phone>+86-15849338280</phone>
    <email>jinshangood@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yun-tian Yang, PhD</last_name>
    <phone>+86-15849338737</phone>
    <email>yangyuntian@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shan Jin</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shan Jin, PhD</last_name>
      <phone>+86-15849338280</phone>
      <email>jinshangood@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yun-Tian Yang, PhD</last_name>
      <phone>+86-15849338737</phone>
      <email>yangyuntian@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gharib H, Papini E. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am. 2007 Sep;36(3):707-35, vi. Review.</citation>
    <PMID>17673125</PMID>
  </reference>
  <reference>
    <citation>Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020. Review.</citation>
    <PMID>26462967</PMID>
  </reference>
  <reference>
    <citation>Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog. 2006 Aug;45(8):613-26.</citation>
    <PMID>16788983</PMID>
  </reference>
  <reference>
    <citation>Sofiadis A, Becker S, Hellman U, Hultin-Rosenberg L, Dinets A, Hulchiy M, Zedenius J, Wallin G, Foukakis T, Höög A, Auer G, Lehtiö J, Larsson C. Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol. 2012 Apr;166(4):657-67. doi: 10.1530/EJE-11-0856. Epub 2012 Jan 24.</citation>
    <PMID>22275472</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>June 24, 2016</last_update_submitted>
  <last_update_submitted_qc>June 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>proteomic</keyword>
  <keyword>cervical lymph node metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

